Background: Low vitamin D levels have been associated with autoimmune disorders and, then, with the Hashimoto’s autoimmune thyroiditis (AT), the most common autoimmune disease. Obesity is characterized by lower vitamin D levels and higher risk to develop autoimmune diseases. The aim of the study was to examine the possibility of an association between AT and decreased 25(OH) vitamin D (25(OH)D) levels in a cohort of otherwise healthy overweight and obese subjects.
Materials and Methods: Two hundred sixty one overweight subjects (mean age: 40.9 + 15.6 years, 200 women and 61 men) were enrolled for this study. All of them did not show any clinically evident metabolic or chronic diseases (i.e. hypertension, diabetes mellitus, renal failure, etc.) and did not use any kind of drug. Serum fasting levels of 25(OH)D, anti-thyroid peroxidase (TPO-Ab) and antithyroglobulin (TG-Ab) antibodies, free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), glucose, uric acid and lipids (triglycerides, total, HDL and LDL cholesterol) were measured. Demographic, anthropometric and clinical parameters (age, body mass index (BMI), waist circumference, blood pressure) were also assessed.
Results: Fifty five percent of all subjects (144/261) showed vitamin D deficiency (≤ 20 ng/ml), and 17% of all individuals had AT (45/261). The percentage of subjects having vitamin D deficiency was significantly higher among those with AT (31 of 45, 69%) than in those without AT (113 of 216, 52%) (χ2= 4.1, p = 0.042). TSH levels were significantly higher in subjects with AT as compared to those without AT (M-W = 7715.5, p < 0.0001). The final logistic model of a multivariate analysis, performed with AT as the dependent variable and sex, age, BMI category, 25(OH)D category, and HDLcholesterol and TSH levels as the independent ones, showed that patients with AT were more likely to have deficiency of 25(OH)D (p = 0.031) and higher TSH (p < 0.005) levels. Seventy six percent of patients with vitamin D deficiency (110 of 144) were obese whereas 59% of patients without vitamin D deficiency were obese (69 of 117) (p=0.003). Waist circumference was different between subjects with deficiency or normal 25 (OH) D levels (p=0.016).
Conclusion: This study clearly shows that vitamin D deficiency is significantly associated to AT in overweight and obese subjects and confirms that obesity is associated to lower vitamin D circulating levels. We suggest that screening for AT should be suggested in all obese subjects with vitamin D deficiency and that vitamin D deficiency should be researched in all obese subjects with AT.
Keywords: Vitamin D, autoimmune thyroiditis, obesity, overweight, subjects, 25(OH)D, TSH.
Tissue-specific Glucocorticoid Signaling May Determine the Resistance Against Glucocorticoids in Autoimmune Diseases
Current Medicinal Chemistry Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Case-control Association Study of Autoimmunity Associated Variants in PDCD1 and Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Pharmacogenomics of Methotrexate: Current Status and Future Outlook
Current Drug Metabolism Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine (Discontinued) Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Current Medicinal Chemistry Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine Autoantibody-Induced Formation of Immune Complexes in Normal Human Serum
Current Pharmaceutical Design NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences (DIscontinued) Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies